Back to Search
Start Over
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
- Source :
-
Haematologica [Haematologica] 2016 Jun; Vol. 101 (6), pp. 717-23. Date of Electronic Publication: 2016 Feb 17. - Publication Year :
- 2016
-
Abstract
- The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed. After a median follow-up of 26.6 months after imatinib discontinuation, 37 patients lost the major molecular response. The probability of sustained major molecular response at 12 months and 24 months was 62.2% and 58.5%, respectively. All 37 patients who lost major molecular response were retreated with imatinib therapy for a median of 16.9 months, and all achieved major molecular response again at a median of 3.9 months after resuming imatinib therapy. We observed newly developed or worsened musculoskeletal pain and pruritus in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal syndrome was associated with a higher probability of sustained major molecular response (P=0.003) and showed a trend for a longer time to major molecular response loss (P=0.098). Positivity (defined as ≥ 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before imatinib discontinuation were associated with a higher probability of sustained major molecular response. Our data demonstrated that the occurrence of imatinib withdrawal syndrome after imatinib discontinuation and longer duration of imatinib were associated with a lower rate of molecular relapse. In addition, minimal residual leukemia measured by digital polymerase chain reaction had a trend for a higher molecular relapse. (Trial registered at ClinicalTrials.gov: NCT01564836).<br /> (Copyright© Ferrata Storti Foundation.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Female
Follow-Up Studies
Fusion Proteins, bcr-abl genetics
Humans
Imatinib Mesylate administration & dosage
Imatinib Mesylate adverse effects
Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
Male
Middle Aged
Neoplasm, Residual genetics
Polymerase Chain Reaction
Prognosis
Protein Kinase Inhibitors administration & dosage
Protein Kinase Inhibitors adverse effects
Recurrence
Retreatment
Time Factors
Treatment Outcome
Antineoplastic Agents therapeutic use
Imatinib Mesylate therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Neoplasm, Residual diagnosis
Protein Kinase Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1592-8721
- Volume :
- 101
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- 26888022
- Full Text :
- https://doi.org/10.3324/haematol.2015.139899